Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2896-2901

  Svenson, Ulrika ^a   Ljungberg, Börje ^b   Roos, Göran ^a,b  

^a Pathology   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; BLOOD; CANCER CELL; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DNA EXTRACTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; KIDNEY CORTEX; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TELOMERE; THROMBOCYTE; ADENOCARCINOMA; CANCER STAGING; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; ULTRASTRUCTURE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TELOMERE;

EID: 66149123737     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3513     Document Type: Article

References (33)

1. Chan SR1 Blackburn EH. Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 2004;359:.109-121.
2. Harley CB. Human ageing and telomeres. Ciba Found Symp 1997;211:129-139.
3. Hacket JA1 Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002;21:619-626.
4. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol MoI Biol Rev 2002;66:407-425.
5. Wu X, Amos CI, Zhu Y, et al. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211-1218
6. McGrath M, Wong JY, Mlchaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 2007;16:815-819.
7. Jang JS, Choi YY, Lee WK1 et al. Telomere length and the risk of lung cancer. Cancer Sei 2008;99:1385-1389
8. Shao L, Wood CG, Zhang D, et al. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 2007;178:1492-1496.
9. Han. J, Qureshi AA, Prescott J, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009;.129:415-21
10. Barwell J1 Pangon L1 Georglou A1 et al. Is telomere length in peripheral blood lymphocytes correlated with cancer susceptibility or radiosensitivity? Br J Cancer 2007:97:1696-1700.
11. Shen J1 Terry MB1 Gurvich I, Liao Y1 Senie RT1 Santella RM. Short telomere length and breast cancer risk: a study in sister sets. Cancer Res 2007;67:5538-5544
12. Svenson U, Nordfjäll K, Stegmayr B, et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 2008;68:3618-3623
13. Risques RA, Vaughan TL, Li X, et al. Leukocyte telomere length predicts cancer risk In Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007:16: 2649-2655
14. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-875
15. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008; 179:2096-2102
16. Kovacs G, Akhtar M, Beckwlth BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997:183:131-3.
17. Sobin LH, Wittekind CH. Eds: International Union Against Cancer (UICC). TNM classification of malignant tumours. 6t.h ed. New York: Wiley-Liss; 2002. p. 193-5.
18. Fuhnnan SA, Lasky LC, Limas C. Prognostic signif- icance of morphologic parameters In renal, cell carcino- ma. Am J Surg Pathol 1982;6:655-663
19. Cawthon RM. Telomere measurement by quantita- tive PCR. Nucleic Adds Res 2002;30:e47.
20. Nordfjäll K1 Osterman P1 Melander O, Nilsson P1 Roos G. hTERT (-I327)T/C polymorphism is not associated with age-related telomere attrition in peripheral blood. Biochem Biophys Res Commun 2007;358:215-218
21. Friedrich U1 Griese E1 Schwab M1 Fritz P1 Thon K1 Klotz U. Telomere length in different tissues of elderly patients. Mech Ageing Dev 2000;119:89-99.
22. Gardner JP, Kimura M, Chai W, et al. Telomere dynamics in macaques and humans. J Gerontol A Biol Sd Med Sd 2007;62:367-374
23. Frankenberger B1 Noessner E1 Schendel DJ. Immune suppression in renal cell carcinoma. Semin Cancer Biol 2007;17:330-343
24. Sakaguchi S1 Yamaguchi T1 Nomura T1 Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-787
25. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells Is increased in peripheral, blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761
26. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T ceUs in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949
27. Viguier M1 Lemaitre F1 Verola O1 et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453
28. Ormandy LA1 HiUemann T1 Wedemeyer H1 et al. Increased populations of regulatory T cells In peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457-2464
29. Hirokawa K, Utsuyama M, Ishikawa T, et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them, through infusion of activated autologous T cells. Mech Ageing Dev 2009:130:86-91.
30. Gertler R1 .Doll D1 Maak M1 Feith M1 Rosenberg R. Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer 2008:112:2173-2180
31. Oh BK, Kim H, Park YN, et al. High telomerase activity and long telomeres in advanced hepatocellular carcino- mas with poor prognosis. Lab Invest 2008:88:144-152
32. Gertler R1 Rosenberg R1 Strieker D1 et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal, carcinoma J Clin Oncol 2004;22:1807-1814.
33. Garcia-Aranda C1 de Juan C1 Diaz-Lopez A1 et al. Correlations of telomere length, telomerase activity, and telomerlc-repeat binding factor I expression in colorec- tal carcinoma. Cancer 2006:106:541-551